Результаты поиска

[Novel action of aldosterone in CsA nephrotoxicity].

Calcineurin inhibitors are helpful immunosuppressive agents in clinical practice. Thanks to their lower cost respect with new immunosuppressive therapy, calcineurin inhibitors in our country continue being the most used treatment in solid organ transplant recipients or patients with autoimmune disease. In the 80's decade cyclosporine A (CsA) was introduced as the first calcineurin inhibitor transforming the immunosuppression therapy. Up to date, many articles evaluating beneficial and adverse effects of CsA have been published. In this review, basic aspects and actions of CsA are analyzed toge

Regulation of myogenic tone and structure of parenchymal arterioles by hypertension and the mineralocorticoid receptor.

Proper perfusion is vital for maintenance of neuronal homeostasis and brain function. Changes in the function and structure of cerebral parenchymal arterioles (PAs) could impair blood flow regulation and increase the risk of cerebrovascular diseases, including dementia and stroke. Hypertension alters the structure and function of large cerebral arteries, but its effects on PAs remain unknown. We hypothesized that hypertension increases myogenic tone and induces inward remodeling in PAs; we further proposed that antihypertensive therapy or mineralocorticoid receptor (MR) blockade would reverse

Aldosterone inhibition and coronary endothelial function in women without obstructive coronary artery disease: an ancillary study of the national heart, lung, and blood institute-sponsored women's ischemia syndrome evaluation.

UNLABELLED: Endothelial dysfunction is highly prevalent and associated with adverse outcomes among patients without obstructive coronary artery disease (CAD). Angiotensin II inhibition may improve endothelial function, but with continued treatment, "aldosterone escape" may occur. Thus, it is unknown if adding aldosterone blockade further improves endothelial function. METHODS: In a double-blind, parallel-group, repeated-measures study, women with symptoms and signs of ischemia, no significant CAD, and coronary endothelial dysfunction receiving an angiotensin-converting enzyme inhibitor or rec

Treating Primary Aldosteronism-Induced Hypertension: Novel Approaches and Future Outlooks.

Primary aldosteronism (PA) is the most common cause of secondary hypertension and is associated with increased morbidity and mortality when compared with blood pressure-matched cases of primary hypertension. Current limitations in patient care stem from delayed recognition of the condition, limited access to key diagnostic procedures, and lack of a definitive therapy option for nonsurgical candidates. However, several recent advances have the potential to address these barriers to optimal care. From a diagnostic perspective, machine-learning algorithms have shown promise in the prediction of P

Stress induced hippocampal mineralocorticoid and estrogen receptor β gene expression and long-term potentiation in male adult rats is sensitive to early-life stress experience.

Glucocorticoid hormones and their receptors have been identified to be involved in emotional and cognitive disorders in early stressed subjects during adulthood. However, the impact of other steroid hormones and receptors has been considered less. Especially, functional roles of estrogen and estrogen receptors in male subjects are largely unknown. Therefore, we measured hippocampal concentrations of 17β-estradiol, corticosterone and testosterone, as well as the gene expression of estrogen receptor α and β (ERα, β), androgen receptor (AR), glucocorticoid (GR) and mineralocorticoid (MR) receptor

Interleukin-21--a biomarker of importance in predicting myocardial function following acute infarction?

INTRODUCTION: Following acute myocardial infarction (AMI), the acute inflammatory response contributes to wound healing but also to progressive myocardial injury. Interleukin-21 (IL-21) plays a key role in immunoregulation; whether IL-21 is associated with left ventricular (LV) remodelling after AMI is unknown. METHODS: Plasma IL-21 concentrations were measured in 100 patients (age 58.9 ± 12.0 years, 77% male) admitted with AMI and LV dysfunction, at baseline (mean 46 h) and again at 24 weeks; cardiac magnetic resonance and measurement of B-type natriuretic peptide, monocyte chemoattractant p

Low-Normal Hemoglobin Concentrations and Clinical Outcomes in Heart Failure.

BACKGROUND: The World Health Organization (WHO) defines anemia as hemoglobin concentration <12 g/dL in women and <13 g/dL in men. Although w … Outcomes In Patients In New York Heart Association [NYHA] Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines [EMPHASIS-HF], NCT00232180; Irbesartan in Heart Failure With Preserved Systolic Function [I-Preserve], NCT00095238; Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved …

Left Ventricular Hypertrophy: Etiology-Based Therapeutic Options.

Determining the etiologies of left ventricular hypertrophy (LVH) can be challenging due to the similarities of the different manifestations in clinical presentation and morphological features. Depending on the underlying cause, not only left ventricular mass but also left ventricular cavity size, or both, may increase. Patients with LVH remain asymptomatic for a few years, but disease progression will lead to the development of systolic or diastolic dysfunction and end-stage heart failure. As hypertrophied cardiac muscle disrupts normal conduction, LVH predisposes to arrhythmias. Distinguishin

Совпадение в полном тексте источника
… In a double blind randomized controlled trial (RCT), similar degrees of LVH regression were provided similarly with eplerenone and enalapril as monotherapies, and the combination of enalapril and eplerenone was found to be more effective in reducing LVM [ 27 ]. … Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003;108(15):1831–1838. doi: 10.1161/01.CIR.0000091405.00772.6E. 28. …

Lifestyle and Pharmacological Interventions to Prevent Anthracycline-Related Cardiotoxicity in Cancer Patients.

Anthracyclines remain a cornerstone of cancer therapy but are associated with a significant risk of cardiotoxicity, which can lead to overt heart failure. The risk is modulated by cumulative dose, pre-existing cardiovascular disease, and patient-specific factors. As cancer survival improves, the long-term cardiovascular consequences of anthracycline exposure have become a growing concern, underscoring the need for effective preventive strategies. This narrative review examines lifestyle and pharmacological interventions aimed at mitigating anthracycline-induced cardiotoxicity. Evidence suggest

Совпадение в полном тексте источника
… eplerenone administration and placebo in patients receiving anthracycline for early or locally advanced breast cancer undergoing [ 93 ]. … Effect of Eplerenone on Diastolic Function in Women Receiving Anthracycline-Based Chemotherapy for Breast Cancer JACC CardioOncology 2019 1 295 298 10.1016/j.jaccao.2019.10.001 34396193 PMC8352029 94. Hundley W.G. D’Agostino R. Jr. Crotts T. Craver K. Hackney M.H. Jordan J.H. Ky B. Wagner L.I. …

Multimodality Imaging Reveals Rare Hereditary Transthyretin Amyloidosis Mimicking Hypertrophic Cardiomyopathy.

BACKGROUND: Distinguishing hypertrophic cardiomyopathy from phenocopies remains a diagnostic challenge in younger patients presenting with unexplained ventricular hypertrophy. CASE SUMMARY: A 52-year-old Moroccan woman previously diagnosed with nonobstructive hypertrophic cardiomyopathy presented with recurrent pericardial chest pain, poorly tolerating angiotensin-converting enzyme inhibitors and beta-blockers. Cardiac magnetic resonance showed asymmetric hypertrophy and papillary muscle hypertrophy suggestive of hypertrophic cardiomyopathy, with markedly elevated native T1 mapping and extrac

Совпадение в полном тексте источника
… Disease-modifying therapy with the transthyretin silencer vutrisiran was initiated, along with standard heart failure therapy including dapagliflozin, eplerenone, and loop diuretics. Outcome and Follow-Up The first dose of vutrisiran was administered in November 2025. …

Cardiac Amyloidosis-Challenging Diagnosis and Unclear Clinical Picture.

Cardiac amyloidosis (CA) is a rare systemic disease determined by the extracellular deposition of amyloid protein in the heart. The protein can accumulate in any part of the heart: myocardium, vessels, endocardium, valves, epicardium and parietal pericardium. The types of CA include the following types: light chain (AL), amyloidosis AA (Amyloid A) and transthyretin (ATTR). The detection of specific subtypes remains of great importance to implement the targeted treatment. We present the case of a 65-year-old woman, who was admitted with severe deterioration of exercise capacity, a bilateral red

Совпадение в полном тексте источника
… During hospitalization, the patients was provided with furosemide and eplerenone, and a low-dose of bisoprolol which resulted in improvement of patient’s condition, and a gradual regression of edema and the amount of fluid in pleural cavities. …

CSI position statement on management of heart failure in India.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Пересадка стволовых клеток и цилтакабтаген Автолеукеля для конъюнктурных множественных миелом и презюмирующих иммуноглобулин тяжелых и легких амилоидозов у пациента с системным Люпусом Эритематосом.

Сопровождение множественных миэломы (ММ), системной иммуноглобулиновой системы освещения (AL) и тяжёлой и световой цепи (AHL) амилоидозом и системной волчанкой (SLE) представляет собой весьма сложную терапевтическую проблему. В то время как химерик антигенрецептора (CAR) T-клентовая терапия B-клеток изменила методы лечения MM, их безопасность и эффективность у пациентов с основными аутоиммунными диатезами и тяжелым амилоидозом органов по-прежнему мало задокументированы. Мы сообщаем о случае 67-летнего афроамериканца с историей SLE, у которого ухудшалась почечная функция и нефротическая протеин

Совпадение в полном тексте источника
… Table 2 Current medication regimen (month 22) Medication | Dosage | Primary indication Torsemide | 20 mg daily | Volume management / edema Eplerenone | 25 mg daily | Heart failure / hypertension Carvedilol | 6.25 mg twice daily with food | Cardioprotection / hypertension Losartan | 50 mg daily | Renoprotection …

Selected abstracts from the XXXVIII National Congress of the Italian Society of Hypertension (SIIA)

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Drug assessment by a Pharmacy and Therapeutics committee: from drug selection criteria to use in clinical practice.

BackgroundIn Spain, hospital medicines are assessed and selected by local Pharmacy and Therapeutics committees (PTCs). Of all the drugs assessed, cancer drugs are particularly important because of their budgetary impact and the sometimes arguable added value with respect to existing alternatives. This study analyzed the PTC drug selection process and the main objective was to evaluate the degree of compliance of prescriptions for oncology drugs with their criteria for use.MethodsThis was a retrospective observational study (May 2007 to April 2010) of PTC-assessed drugs. The variables measured

Совпадение в полном тексте источника
… Year | Drug (therapeutic group a ) Not included n=8 (20%) | Included n=32 (80.0%) With criteria for use n=28 (87.5%) | Without criteria for use n=4 (12.5%) May 2007 to April 2008 | Eplerenone (C03DA) | Glutamine (B05XB) | Clonidine (C02AC) Botulinum toxin type B (M03AX) | Bortezomib (L01XX) b | Levetiracetam …

Albuminuria as a diagnostic criterion and a therapeutic target in heart failure and other cardiovascular disease.

The high disease burden and bidirectional relationship of chronic kidney disease (CKD), heart failure (HF) and other cardiovascular disease (CVD) necessitate the need for early diagnosis of these diseases. While current screening and detection methods are recommended by CKD and CVD guidelines, their adoption in practice is low. Urine albumin-to-creatinine ratio (uACR) is recognized as a diagnostic marker for CKD and a prognostic marker for CKD progression, HF and CVD outcomes, therefore albuminuria changes have been accepted as a surrogate outcome for kidney and cardiovascular endpoints. Furth

Совпадение в полном тексте источника
… (mg/g [IQR]) Normalbuminuria: 9 (5–18) Microalbuminuria: 79 (45–142) Macroalbuminuria: 704 (451–1393) | Placebo‐adjusted GMR of 1 year to baseline uACR All patients: 0.61 (0.49–0.77) Normalbuminuria: 0.65 (0.48–0.89) Microalbuminuria: 0.78 (0.55–1.11) Macroalbuminuria: 0.24 (0.10–0.56) EMPASIS‐HF (eplerenone … Eplerenone in patients with systolic heart failure and mild symptoms . N Engl J Med 2011 ; 364 : 11 – 21 . 10.1056/NEJMoa1009492 21073363 64 Agarwal R , Rossignol P , Romero A , Garza D , Mayo MR , Warren S , et al . …

An approach to treating older adults with chronic kidney disease.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Class | Examples Angiotensin-converting enzyme inhibitors | Perindopril, ramipril, lisinopril Angiotensin receptor blockers | Candesartan, telmisartan, irbesartan Aldosterone antagonists | Spironolactone, eplerenone Sodium–glucose cotransporter 2 inhibitors | Empagliflozin, dapagliflozin, canagliflozin …